|Assessment Status||Rapid Review Complete|
|Indication||Tezepelumab (Tezspire®) is indicated as add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma, who are inadequately controlled despite high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.|
|Rapid review commissioned||10/05/2023|
|Rapid review completed||15/06/2023|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that tezepelumab not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.